2022-10-10T13:32:58-05:00 2021-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2021-01-01 911893957 THE MAX FOUNDATION MAXF 4257788660 1107 NE 45TH 230 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2022-10-05 1 PATRICIA PEARCE 999009999 JENNIFER BECKER HARRIS P00183358 4254544919 2022-10-05 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z PATRICIA M PEARCE 1107 NE 45TH 230 SEATTLE WA 98105 4935983 0 X WWW.THEMAXFOUNDATION.ORG X 1997 WA WE ARE ON A MISSION TO ACCELERATE HEALTH EQUITY BY DELIVERING MEDICATION, TECHNOLOGY, AND SERVICES TO PATIENTS FACING CANCER AND OTHER CRITICAL ILLNESSES, FOCUSING OUR ENERGY ON THOSE NO ONE ELSE IS HELPING. 8 7 23 635 0 0 6430918 1018778 3908320 3900915 -387 -1103 10 -69711 10338861 4848879 22805247 532668 0 0 2576929 2670391 0 0 563284 1875661 1864715 27257837 5067774 -16918976 -218895 3335898 2817836 605558 306391 2730340 2511445 X AT THE MAX FOUNDATION WE BELIEVE THAT ALL PEOPLE LIVING WITH CANCER SHOULD BE ABLE TO ACCESS HIGH IMPACT MEDICINES, THAT GEOGRAPHY SHOULD NOT DICTATE ONE'S DESTINY, AND THAT EVERYONE SHOULD BE ABLE TO STRIVE FOR HEALTH WITH DIGNITY AND HOPE. WE ARE ON A MISSION TO ACCELERATE HEALTH EQUITY BY DELIVERING MEDICATION, TECHNOLOGY, AND SERVICES TO PATIENTS FACING CANCER AND OTHER CRITICAL ILLNESSES, FOCUSING OUR ENERGY ON THOSE NO ONE ELSE IS HELPING. 0 0 2880695 532668 3900915 A KEY FOCUS OF THE MAX FOUNDATION IS EXPANDING HUMANITARIAN ACCESS TO INNOVATIVE TREATMENTS FOR CANCER AND OTHER CRITICAL ILLNESSES IN LOW-AND MIDDLE-INCOME COUNTRIES. DONATIONS OF HIGH IMPACT PRODUCTS FROM DRUG MANUFACTURERS ARE RECEIVED BY OUR SUPPORT ORGANIZATION, MAXAID, AND CHANNELED TO INDIVIDUAL PATIENTS VIA OUR NETWORK OF HEALTHCARE PROVIDERS AND CANCER TREATMENT CENTERS. THIS ACCESS TO MEDICINES IS ENABLED THROUGH OUR PATIENT-CENTERED TREATMENT ACCESS MODEL KNOWN AS MAX ACCESS SOLUTIONS. OUR PRIMARY CLIENT IS A PATIENT WHO IS TREATED BY ONE OF OUR PARTNER PHYSICIANS, DIAGNOSED WITH A SPECIFIC CANCER OR CRITICAL ILLNESS, AND PRESCRIBED A MEDICATION FOR WHICH THE ONLY AVAILABLE FORM OF ACCESS IS A HUMANITARIAN CHANNEL THROUGH MAX ACCESS SOLUTIONS. WE USE A SOPHISTICATED WEB-ENGINE PLATFORM DEVELOPED IN-HOUSE TO ALLOW US TO WORK IN REAL TIME WITH HEALTHCARE PROVIDERS AND CREATE INDIVIDUALIZED PROGRAM LIFE CYCLES TO MEET EACH PATIENT'S NEEDS. WE FURTHER ACT AS HEALTHCARE NAVIGATORS FOR THESE PATIENTS, HELPING THEM WALK THROUGH THE ACCESS PROGRAM ENVIRONMENT. IN ORDER TO OPTIMIZE TREATMENT, WITHIN OUR CAPABILITIES WE PROVIDE CRUCIAL SUPPORT THAT INCLUDES ACCESS TO DIAGNOSTIC TESTING, EMOTIONAL AND LOGISTICAL SUPPORT, INFORMATIONAL RESOURCES AND EDUCATION, AS WELL AS ADVOCATING ON THEIR BEHALF WHEN NEEDED. WE STRENGTHEN THE COMMUNITIES AROUND PATIENTS BY SUPPORTING PATIENT ORGANIZATIONS AND CREATING AWARENESS INITIATIVES IN LOCAL AND GLOBAL COMMUNITIES. 2880695 1 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 1 1 0 1 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 1 1 1 0 0 1 X 10 0 23 1 0 1 IN MY TH SF 0 0 0 1 1 0 0 0 0 0 0 X 8 7 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA HI NY PA X X PATRICIA M PEARCE 4257788660 1107 NE 45TH 230 SEATTLE WA 98105 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 50.00 5.00 X X 273138 0 16137 PAULA BOULTBEE BOARD CHAIR 5.00 2.00 X X 0 0 0 TRACEY HIGGINS BOARD VICE CHAIR 5.00 2.00 X X 0 0 0 CURT MALLOY BOARD TREASURER 5.00 2.00 X X 0 0 0 MIKA MATSUZAKI BOARD SECRETARY 5.00 2.00 X X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 5.00 2.00 X 0 0 0 SUSAN JERIAN BOARD MEMBER 5.00 2.00 X 0 0 0 MABEL WOLOJ BOARD MEMBER 5.00 2.00 X 0 0 0 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 40.00 2.00 X 185191 0 13246 BYRAN MURPHY VICE PRESIDENT, PROGRAMS 40.00 2.00 X 174178 0 9125 CRAIG ANDERSON DIRECTOR OF IT 40.00 0.00 X 120944 0 14893 WILMA COMENAT VICE PRESIDENT, DEVELOPMENT 40.00 2.00 X 144349 0 10208 NEAL PARRY SR. SUPPLY CHAIN MANAGER 40.00 0.00 X 118100 0 14699 MICHAEL WRIGGLESWORTH SR. DIRECTOR OF PROGRAMS STRATEGY 40.00 0.00 X 125262 0 124 1141162 0 78432 7 0 1 0 KOMO 140 4TH AVE N SEATTLE WA 98109 ADVERTISING 244668 1 214044 296372 508362 239388 1018778 PATIENT CARE 624100 3864090 3864090 MEDICAL TEST KITS 624100 36825 36825 3900915 5 5 17 17 0 1108 -1108 -1108 -1108 16268 214044 85996 -69728 -69728 4848879 3900915 0 -70814 10000 10000 522668 522668 671015 183303 487712 54676 54676 1657378 973474 246935 436969 128646 50936 51415 26295 158676 63577 66488 28611 7776 7776 102100 43640 58460 228573 68068 145893 14612 262398 260212 2186 105223 12544 76366 16313 95611 13525 82086 165657 106868 40855 17934 57141 40955 14547 1639 13407 1289 12049 69 2017 2017 86746 34734 33356 18656 26186 26186 COUNTRY REPRESENTATIVES 686713 686713 DISTRIBUTION & SHIPPING 1495 1495 23672 12230 11442 5067774 2880695 1623795 563284 1258331 892681 62455 40252 90000 26000 16245 11543 137551 0 73312 152521 467963 263793 287022 204170 1410982 1490669 3335898 2817836 209483 236241 99703 70150 296372 0 605558 306391 X 1026770 599088 1703570 1912357 2730340 2511445 3335898 2817836 -218895 0 X X 0 1 X 1 0 X 18308593 27791248 57006075 6430918 807768 110344602 18308593 27791248 57006075 6430918 807768 110344602 96992016 13352586 5434 4483 25 24 22 9988 3693 1022 18869 23584 110378174 16838154 0.12100 0.13530 X THE MAX FOUNDATION QUALIFIES AS A PUBLICLY SUPPORTED CHARITY UNDER THE FACTS AND CIRCUMSTANCES EXCEPTION PROVIDED TO IRC SECTION 509(A)(1) CHARITIES UNDER TREAS. REG. SEC. 1.170A-9(E)(3). THE FOUNDATION DOES NOT RECEIVE AT LEAST ONE THIRD OF ITS SUPPORT FROM THE PUBLIC. IT DOES HOWEVER MEET THE TESTS REQUIRED UNDER THE FACTS AND CIRCUMSTANCE TEST: I. THE FOUNDATION NORMALLY MEETS THE PUBLIC SUPPORT TEST AS PROVIDED IN THE REGULATIONS. THE AGGREGATE PUBLIC SUPPORT PERCENTAGE FOR THE YEARS ENDED DECEMBER 31, 2020, 2019, 2018, AND 2017, IS 13.99%, 17.27%, 27.73%, AND 41.45%, RESPECTIVELY. II. THE FOUNDATION CARRIES ON A BONA FIDE CONTINUOUS PUBLIC SOLICITATIONS PROGRAM. ITS FUNDRAISING EFFORTS INCLUDE ANNUAL MAILINGS TO SOLICIT FUNDS, PUBLISHING OF AN ANNUAL REPORT TO EDUCATE ITS DONOR BASE AND FURTHER SOLICIT DONATIONS, AND OTHER FUNDRAISING ACTIVITES. IN 2021, THE FOUNDATION HELD A VIRTUAL FUNDRAISING GALA AFTER BEING UNABLE TO HOLD ITS ANNUAL FUNDRAISING GALA, DUE TO COVID-19 SOCIAL DISTANCING RESTRICTIONS IN 2020. THE 2021 VIRTUAL GALA RAISED NEARLY $90,000. THE 2019 GALA HAD RAISED NEARLY $143,000 WHICH WAS A MARKED INCREASE FROM OUR 2017 FIRST GALA WHICH RAISED OVER $98,000. THE FOUNDATION'S PEER-TO-PEER CAMPAIGN, MAX-A-THON WAS HELD AGAIN IN 2021 RAISING OVER $63,000. THIS WAS A 58% INCREASE OVER ITS FIRST YEAR RECEIPTS OF CLOSE TO $40K IN 2020. IN 2017 AND 2018 WE ALSO HAD INTERNATIONAL FUNDRAISING EVENTS CALLED MAX GLOBAL EXPERIENCE WHICH RAISED OVER $109,000 AND OVER $80,000, RESPECTIVELY, FROM THE GENERAL PUBLIC. DUE TO THE PANDEMIC, MAX GLOBAL EXPERIENCE WAS NOT HELD IN 2020 OR 2021 BUT PLANS ARE UNDERWAY FOR 2022. SINCE 2017, FIVE MULTINATIONAL PHARMACEUTICAL COMPANIES JOINED THE FOUNDATION IN WHAT WE CALL A HUMANITARIAN PARTNERSHIP FOR ACCESS TO CANCER TREATMENT (PACT). THROUGH THESE HUMANITARIAN COLLABORATIONS, EACH COMPANY HAS COMMITTED TO DONATE PRESCRIBED MEDICATIONS FOR A DIFFERENT NUMBER OF PATIENTS WITHIN THEIR CAPABILITIES, AND ALL HAVE COMMITTED THEIR SUPPORT FOR AS LONG AS EACH PATIENT NEEDS IT. CANCER TREATMENT DONATIONS ARE RECEIVED THROUGH OUR SUPPORT ORGANIZATION, MAXAID. IN 2021, $445,775,299 IN DRUGS AND MEDICAL SUPPLIES WERE RECEIVED BY MAXAID TO FURTHER THE MISSION OF THE MAX FOUNDATION.III. DURING THE YEARS ENDED DECEMBER 31, THE FOUNDATION HAD THE FOLLOWING SUPPORTERS, RESPECTIVELY: 2017:INDIVIDUALS - 676 CORPORATIONS - 35 FOUNDATIONS - 2TOTAL - 7132018:INDIVIDUALS - 377 CORPORATIONS - 42 FOUNDATIONS - 2TOTAL - 4212019:INDIVIDUALS - 183CORPORATIONS - 35FOUNDATIONS - 0TOTAL - 2182020:INDIVIDUALS - 245CORPORATIONS - 34FOUNDATIONS - 2TOTAL - 2812021:INDIVIDUALS - 472CORPORATIONS - 35FOUNDATIONS - 1TOTAL - 508IV. THE PUBLIC NATURE OF THE FOUNDATION'S GOVERNING BOARD THE FOUNDATION HAS A BOARD OF DIRECTORS THAT INCLUDES PROFESSIONALS, COMMUNITY LEADERS, AND OTHER PERSONS WITH EXPERTISE IN DIFFERENT DISCIPLINES. IN ADDITION, THE FOUNDATION HAS SEVERAL MEDICAL ADVISORY BOARDS. OUR MEDICAL ADVISORY BOARDS INCLUDE SPECIALISTS WHO ARE KEY OPINION LEADERS IN THE FIELD OF ONCOLOGY AND HEMATOLOGY. THESE EXPERT PHYSICIANS PROVIDE GUIDANCE TO THE STRUCTURE OF OUR PROGRAMS. V. THE FOUNDATION SUPPORTS GLOBAL HEALTH EFFORTS BY :- CREATING ACCESS CHANNELS TO INNOVATIVE CANCER MEDICINES FOR PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES WHERE NO OTHER MEANS OF ACCESS EXISTS. - MAKING TREATMENT, CARE, AND SUPPORT AVAILABLE IN LOW- AND MIDDLE- INCOME COUNTRIES AND THEREBY PREVENTING AVOIDABLE CANCER DEATHS AROUND THE WORLD.- CREATING A MODEL THAT ENABLES THE PRIVATE SECTOR TO HELP CANCER PATIENTS IN NEED.- STRENGTHENING HEALTH SYSTEMS AND LOCAL SUPPORTS THROUGH WRAPAROUND SERVICES FOR PATIENTS AND THEIR COMMUNITIES. VI. MAX ACCESS SOLUTIONS IS THE FOUNDATION'S OPERATIONAL PROGRAM THROUGH WHICH HUMANITARIAN DONATIONS OF APPROVED MEDICINES ARE CHANNELED TO PATIENTS IN NEED. MAX ACCESS SOLUTIONS IS DESIGNED TO BE A BRIDGE FOR ACCESS TO TREATMENT SPECIFICALLY WITHIN LOW- AND MIDDLE-INCOME COUNTRIES WHERE THE BURDEN OF DISEASE IS HIGH AND LOCAL GOVERNMENT ACCESS PROGRAMS MAY NOT BE CURRENTLY FEASIBLE.WITHIN MAX ACCESS SOLUTIONS, COMPANIES DONATE PRODUCT TO THE FOUNDATION AND THE ORGANIZATION CHANNELS PRODUCT AT ITS DISCRETION TO PATIENTS IN NEED THROUGH THEIR TREATING PHYSICIAN AND WITHIN THE SCOPE OF ITS COLLABORATION AGREEMENTS. VETTED HEALTH CARE PROVIDERS IN LOW- AND MIDDLE-INCOME COUNTRIES INITIATE THE PRODUCT REQUEST AND MANAGE TREATMENT OF PATIENTS RECEIVING PRODUCT FROM THE FOUNDATION. THE FOUNDATION WORKS THROUGH A THIRD-PARTY LOGISTICS PROVIDER WHO, AS ITS AGENT, RECEIVES PRODUCT FROM MANUFACTURERS AND SHIPS IT TO END USERS ON THE ORGANIZATION'S BEHALF.AT THE CENTER OF OUR MODEL IS A PATIENT WHO HAS BEEN DIAGNOSED WITH CANCER BY ONE OF OUR PARTNER PHYSICIANS AND PRESCRIBED A TREATMENT IN OUR PORTFOLIO FOR WHICH NO LOCAL ACCESS EXISTS. WORKING IN COLLABORATION WITH A ROBUST NETWORK OF LEADING CANCER TREATING INSTITUTIONS AND PHYSICIANS, DRUG MANUFACTURERS, AN INTERNATIONAL DISTRIBUTOR, AND LOCAL PATIENT SUPPORT ORGANIZATIONS, WE PROVIDE HUMANITARIAN ACCESS TO THE TREATMENT WITH THE AIM THAT EACH REQUIRED DAILY DOSE REACHES THE INTENDED PATIENT AT THE RIGHT TIME, WHILE STRENGTHENING THE LOCAL HEALTHCARE SYSTEM.IN 2021, THE FOUNDATION PROVIDED SERVICES TO 34,235 INDIVIDUAL CANCER PATIENTS IN 75 COUNTRIES INCLUDING DELIVERING 9.1 MILLION DAILY DOSES OF CRITICAL CANCER TREATING MEDICATION, PROVIDING 6,128 MOLECULAR DIAGNOSTIC TESTS, AND ORGANIZING AND DELIVERING 28 AWARENESS EVENTS AND ONLINE PATIENT EDUCATION SESSIONS, IN PARTNERSHIP WITH A GLOBAL NETWORK OF 380 MEDICAL INSTITUTIONS AND 520 DOCTORS. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2017 AMOUNT: $ 3,693. 2018 AMOUNT: $ 1,022. 2019 AMOUNT: $ 18,869. 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 243580 131158 112422 165083 120775 44308 59300 11860 47440 204170 LEASE DEPOSIT 15048 DUE FROM MAXAID 1475621 1490669 1 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 151000 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 108000 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 89000 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 76000 NORTH AMERICA 0 2 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 69000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 24000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 4000 SOUTH ASIA 1 21 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 771000 SUB-SAHARAN AFRICA 1 7 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 321000 EAST ASIA AND THE PACIFIC 2 8 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 219000 SOUTH AMERICA 0 6 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 169000 SOUTH AMERICA 0 0 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 69000 RUSSIA AND NEIGHBORING STATES 0 2 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 48000 CENTRAL AMERICA AND THE CARIBBEAN 0 2 EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 46000 EAST ASIA AND THE PACIFIC 0 0 FUNDRAISING EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING 1 23 3 25 4 48 1292000 872000 2164000 RUSSIA AND NEIGHBOURING STATES DIAGNOSTIC TESTING 0 37230 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 30000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SOUTH AMERICA DIAGNOSTIC TESTING 0 29435 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SOUTH ASIA DIAGNOSTIC TESTING 0 25000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 0 25000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SOUTH AMERICA DIAGNOSTIC TESTING 0 25000 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBOURING STATES DIAGNOSTIC TESTING 0 23970 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 300 WIRE TRANSFER 20175 DIAGNOSTIC EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 18680 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBOURING STATES DIAGNOSTIC TESTING 0 15145 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 14841 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 0 12975 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBOURING STATES DIAGNOSTIC TESTING 0 12750 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT EAST ASIA AND THE PACIFIC DIAGNOSTIC TESTING 0 11915 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 7950 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 0 6280 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 5850 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT EAST ASIA AND THE PACIFIC DIAGNOSTIC TESTING 0 5850 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 5750 DIGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 5500 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 5250 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 0 5114 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT 22 0 DRUG SOUTH ASIA 15815 0 63542 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 9824 0 39471 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND NEIGHBORING STATES 4271 0 17160 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG CENTRAL AMERICA AND THE CARIBBEAN 1520 0 6107 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 1335 0 5540 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE TRANSPORTATION ASSISTANCE SOUTH AMERICA 7 5345 WIRE TRANSFER 0 DRUG EAST ASIA AND THE PACIFIC 779 0 3130 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG NORTH AMERICA 599 0 2707 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE TRANSPORTATION ASSISTANCE CENTRAL AMERICA AND THE CARIBBEAN 6 1800 WIRE TRANSFER 0 TRANSPORTATION ASSISTANCE NORTH AMERICA 4 1200 WIRE TRANSFER 0 TRANSPORTATION ASSISTANCE EAST ASIA AND THE PACIFIC 3 900 WIRE TRANSFER 0 TRANSPORTATION ASSISTANCE RUSSIA AND NEIGHBORING STATES 2 600 WIRE TRANSFER 0 DRUG MIDDLE EAST AND NORTH AFRICA 77 0 309 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE PROVIDER SUPPORT RUSSIA AND NEIGHBORING STATES 1 0 200 TABLET COMPUTER FAIR MARKET VALUE DRUG EUROPE (INCLUDING ICELAND & GREENLAND) 15 0 60 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 1 1 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILLMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART III ACCOUNTING METHOD: PART IV, LINE 1 FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). MAXIMIZE LIFE GALA 167075 151577 15498 9785 4500 53453 MAX-A-THON 63237 62467 770 500 17758 230312 214044 16268 10285 4500 71211 85996 -69728 1 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N - PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 10000 0 SUPPORT FOR "SPOT ON" DIAGNOSTIC TESTING 1 0 PART I, LINE 2: ALL GRANTS TO US ENTITIES ARE MADE SUBJECT TO AN AWARD LETTER THAT CLEARLY DEFINES THE GRANTS SCOPE. PROGRAM TEAM MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. X X X X 0 0 0 0 0 0 0 1 0 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 235638 0 37500 0 0 0 0 0 16137 0 289275 0 0 0 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 185191 0 0 0 0 0 0 0 13246 0 198437 0 0 0 BYRAN MURPHY VICE PRESIDENT, PROGRAMS 174178 0 0 0 0 0 0 0 9125 0 183303 0 0 0 WILMA COMENAT VICE PRESIDENT, DEVELOPMENT 144349 0 0 0 0 0 0 0 10208 0 154557 0 0 0 PART I, LINE 7 PATRICIA GARCIA-GONZALEZ, CEO, RECEIVED A NON-FIXED PAYMENT IN THE FORM OF A BONUS, PURSUANT TO HER EMPLOYMENT AGREEMENT. THE BONUS WAS REVIEWED AND APPROVED BY THE BOARD BASED ON HER PERFORMANCE AND A VARIETY OF OTHER FACTORS. INES GARCIA-GONZALEZ SEE PART V 54676 SEE PART V 0 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: INES GARCIA GONZALEZ(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF PATRICIA GARCIA-GONZALEZ, CEO.(D) DESCRIPTION OF TRANSACTION: CONTRACTOR X 2 13268 FAIR MARKET VALUE X 17 211010 FAIR MARKET VALUE X AUCTION ITEMS 17 15110 FAIR MARKET VALUE 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE TOTAL CONTRIBUTIONS RECEIVED. FORM 990, PART I, LINE 6, VOLUNTEERS: PARTNER HEALTHCARE PROVIDERS VOLUNTEER THEIR TIME TO FULFILL ALL OBLIGATIONS RELATED TO PRESCRIBING, APPLYING FOR TREATMENT ACCESS REQUESTS ON BEHALF OF INDIVIDUAL PATIENTS, SUPPORT LOGISTICS AND OBTAINING IMPORT PERMITS FROM LOCAL HEALTHCARE AUTHORITIES, OVERSEE USE AND DISPENSATION OF DONATED PRODUCTS AND OTHER ACTIVITIES RELATED TO THEIR OBLIGATIONS WITHIN THE MAX ACCESS SOLUTIONS. IN 2021, THERE WERE 520 HEALTHCARE PROVIDERS IN OUR NETWORK. THERE ARE 8 VOLUNTEER BOARD MEMBERS AND 30 MEMBERS OF OUR MEDICAL & STRATEGIC ADVISORY BOARD. ADDITIONALLY, WE WORKED WITH 66 VOLUNTEERS TO ORGANIZE EDUCATION AND AWARENESS EVENTS. ELEVEN VOLUNTEERS ASSISTED WITH FUNDRAISING EVENTS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD HAS ADOPTED A CONFLICT OF INTEREST POLICY AND THE POLICY IS REVIEWED ON AN ANNUAL BASIS. EACH YEAR, BOARD MEMBERS AND OFFICERS MUST REVIEW THE POLICY AND DETERMINE IF ANY CONFLICT OF INTERESTS EXIST. ANNUALLY, THE DISCLOSURES WERE REVIEWED BY THE EXECUTIVE ASSISTANT. SHOULD A CONFLICT ARISE, IT WOULD BE REVIEWED BY THE CFO, CEO AND BOARD TREASURER. NO BOARD MEMBER OR OFFICER MAY VOTE ON ANY MATTER UNDER CONSIDERATION IN WHICH SUCH PERSON HAS A CONFLICT OF INTEREST. FURTHER, ANY PERSON WITH A MATERIAL CONFLICT OF INTEREST IN ANY DECISION SHOULD BE ABSENT FROM THE ROOM DURING THE BOARD'S REVIEW, INCLUDING ITS VOTE, ON THE DECISION IN QUESTION. FORM 990, PART VI, SECTION B, LINE 15 THE CEO HAS AN UPDATED CONTRACT WITH THE BOARD FOR A PERIOD OF FIVE YEARS, COMMENCING JULY 1, 2021. IN THIS CONTRACT, A BASE SALARY AND A YEARLY PERCENTAGE INCREASE HAS BEEN ESTABLISHED, AS WELL AS A YEARLY BONUS. EXTERNAL COMPENSATION ANALYSIS AND A WRITTEN PERFORMANCE EVALUATION WERE INCLUDED IN THE RENEWAL OF THE CEO CONTRACT. . THE CFO WAS OFFICIALLY HIRED AS AN EMPLOYEE IN JULY 2018. BOTH THE CEO AND THE BOARD REVIEWED AND DETERMINED COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART XII, LINE 2B AND PART IV LINE 12A ACTIVITY REPORTED ON THIS FORM 990 AND ITS AUDITED FINANCIAL STATEMENTS INCLUDES ALL ACTIVITY FOR ENTITIES REPORTED ON SCHEDULE R. MAXSTATION MALAYSIA SDN BHD UNIT 1302 LOBBY 1 BLOCK A DAMAN SELANGOR MY 320492996 PATIENT ORIENTED PROGRAMS MY 56383 18623 THE MAX FOUNDATION MAXAID 1107 NE 45TH NO 230 SEATTLE WA 98105 352577906 SUPPORT MAX FOUNDATION WA 501(C)(3) LINE 12A, I THE MAX FOUNDATION 1 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF 0186 TO SUPPORT MAX FOUNDATION SF MAX FOUNDATION T -7425 3226 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 MAXAID L 3826195 BOOK